These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9519015)

  • 1. Speed of anticoagulation in DVT.
    Douglas M; Strelnick A
    J Fam Pract; 1998 Mar; 46(3):202. PubMed ID: 9519015
    [No Abstract]   [Full Text] [Related]  

  • 2. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.
    Hull RD; Raskob GE; Brant RF; Pineo GF; Valentine KA
    Arch Intern Med; 1997 Dec 8-22; 157(22):2562-8. PubMed ID: 9531224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anticoagulation in stroke. Evidence-based and empirical indications].
    Walter U; Kloth A; Benecke R; Kunesch E
    Dtsch Med Wochenschr; 2003 Oct; 128(42):2200-5. PubMed ID: 14562219
    [No Abstract]   [Full Text] [Related]  

  • 4. Thromboprophylaxis.
    Bailey S; Campbell J; Haines S
    J Neurosurg; 2002 Apr; 96(4):807-8; author reply 808-9. PubMed ID: 11990828
    [No Abstract]   [Full Text] [Related]  

  • 5. Thromboprophylaxis.
    Walsh DC; Kakkar AK
    J Neurosurg; 2002 Apr; 96(4):806-7; author reply 807. PubMed ID: 11990827
    [No Abstract]   [Full Text] [Related]  

  • 6. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.
    Greaves M;
    Thromb Haemost; 2002 Jan; 87(1):163-4. PubMed ID: 11848446
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised evaluation of treatment modalities in thromboembolic disorders.
    ten Cate JW; Büller HR
    Haematologica; 1999 Jun; 84 Suppl EHA-4():85-7. PubMed ID: 10907478
    [No Abstract]   [Full Text] [Related]  

  • 9. [LMWH and UFH in direct comparison. Consent: CERTIFY].
    MMW Fortschr Med; 2007 May; 149(20):53. PubMed ID: 18051967
    [No Abstract]   [Full Text] [Related]  

  • 10. When can the patient with deep venous thrombosis begin to ambulate?
    Aldrich D; Hunt DP
    Phys Ther; 2004 Mar; 84(3):268-73. PubMed ID: 14984299
    [No Abstract]   [Full Text] [Related]  

  • 11. [Double-blind cross-over controlled study on a calcium-heparin preparation].
    Marsala F
    Clin Ter; 1985 Jun; 113(6):473-7. PubMed ID: 3896621
    [No Abstract]   [Full Text] [Related]  

  • 12. [Deep venous thrombosis--treatment].
    Fries R; Böhm M
    Dtsch Med Wochenschr; 2003 May; 128(18):999-1002. PubMed ID: 12721879
    [No Abstract]   [Full Text] [Related]  

  • 13. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study.
    Birnbaum J; Spies CD; Klotz E; Hein OV; Morgera S; Schink T; Ziemer S; Grund MS; Saalmann R; Kox WJ; Lehmann C
    Ren Fail; 2007; 29(3):271-7. PubMed ID: 17497439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory control of continuous intravenous heparin therapy with Howel time and activated partial thromboplastin time. A prospective, randomized and blind study.
    Almazan A; Lozano F; Ramos M; Rodriguez-Moran M; Gomez-Alonso A
    Angiology; 1985 Jun; 36(6):363-9. PubMed ID: 4025944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring the effect of heparin bolus during percutaneous coronary angioplasty (PTCA): assessment of three bedside coagulation monitors.
    Hézard N; Metz D; Potron G; Nazeyrollas P; Maes D; Droulle C; Mulpas MC; Elaerts J; Nguyen P
    Thromb Haemost; 1998 Nov; 80(5):865-6. PubMed ID: 9843190
    [No Abstract]   [Full Text] [Related]  

  • 16. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
    Anand SS; Yusuf S; Pogue J; Ginsberg JS; Hirsh J;
    Circulation; 2003 Jun; 107(23):2884-8. PubMed ID: 12796128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration.
    Kozek-Langenecker SA; Spiss CK; Michalek-Sauberer A; Felfernig M; Zimpfer M
    Crit Care Med; 2003 Mar; 31(3):864-8. PubMed ID: 12626998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Low-molecular-weight heparin without oral anticoagulants for the treatment of deep vein thrombosis].
    Alonso Martínez JL; Abínzano Guillén ML; Urbieta Echezarreta MA; Annichérico Sánchez FJ; Fernández Ladrón V; García Sanchotena JL
    An Med Interna; 2008 Jan; 25(1):4-8. PubMed ID: 18377187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial.
    Kozek-Langenecker SA; Spiss CK; Gamsjäger T; Domenig C; Zimpfer M
    Wien Klin Wochenschr; 2002 Feb; 114(3):96-101. PubMed ID: 12060975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin dosing: a comparison of weight-based dosing vs standard dosing.
    White CM
    Conn Med; 1997 Feb; 61(2):103-4. PubMed ID: 9066199
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.